Parallel Advisors LLC Takes $171,000 Position in Structure Therapeutics Inc. Sponsored ADR $GPCR

Parallel Advisors LLC acquired a new stake in shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 8,264 shares of the company’s stock, valued at approximately $171,000.

Other hedge funds have also recently made changes to their positions in the company. GF Fund Management CO. LTD. bought a new stake in shares of Structure Therapeutics during the fourth quarter valued at approximately $34,000. National Bank of Canada FI raised its position in shares of Structure Therapeutics by 1,448.2% in the 1st quarter. National Bank of Canada FI now owns 2,957 shares of the company’s stock worth $51,000 after purchasing an additional 2,766 shares during the last quarter. ANTIPODES PARTNERS Ltd raised its position in shares of Structure Therapeutics by 310.7% in the 1st quarter. ANTIPODES PARTNERS Ltd now owns 4,247 shares of the company’s stock worth $74,000 after purchasing an additional 3,213 shares during the last quarter. GAMMA Investing LLC lifted its holdings in shares of Structure Therapeutics by 663.8% during the first quarter. GAMMA Investing LLC now owns 8,776 shares of the company’s stock valued at $152,000 after purchasing an additional 7,627 shares in the last quarter. Finally, Quantbot Technologies LP bought a new position in shares of Structure Therapeutics during the first quarter valued at $249,000. 91.78% of the stock is owned by hedge funds and other institutional investors.

Structure Therapeutics Stock Performance

Shares of GPCR stock opened at $24.45 on Tuesday. Structure Therapeutics Inc. Sponsored ADR has a 52-week low of $13.22 and a 52-week high of $45.37. The firm has a market capitalization of $1.41 billion, a P/E ratio of -23.29 and a beta of -1.89. The stock has a 50 day moving average price of $19.31 and a 200 day moving average price of $20.65.

Structure Therapeutics (NASDAQ:GPCR) last issued its quarterly earnings results on Wednesday, August 6th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.08). As a group, sell-side analysts forecast that Structure Therapeutics Inc. Sponsored ADR will post -0.82 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on GPCR shares. HC Wainwright lowered their price target on Structure Therapeutics from $75.00 to $60.00 and set a “buy” rating on the stock in a report on Thursday, August 7th. Guggenheim lowered their target price on Structure Therapeutics from $92.00 to $90.00 and set a “buy” rating on the stock in a report on Thursday, August 7th. JMP Securities lowered their target price on Structure Therapeutics from $89.00 to $87.00 and set a “market outperform” rating on the stock in a report on Thursday, August 7th. Lifesci Capital raised Structure Therapeutics to a “strong-buy” rating in a report on Monday, September 8th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $65.00 target price on shares of Structure Therapeutics in a report on Monday, June 23rd. One research analyst has rated the stock with a Strong Buy rating and seven have assigned a Buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $68.67.

Structure Therapeutics Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.